Outcomes of COVID-19 in the Eastern Mediterranean Region in the first 4 months of the pandemic

References

1. ↵
   1. Biswas A,
   2. Bhattacharjee U,
   3. Chakrabarti AK,
   4. Tewari DN,
   5. Banu H,
   6. Dutta S

   Emergence of Novel Coronavirus and COVID-19:whether to stay or die out? Crit Rev Microbiol 2020:1–12.
2. ↵
   1. Gorbalenya AE,
   2. Baker SC,
   3. Baric RS,
   4. de Groot RJ,
   5. Drosten C,
   6. Gulyaeva AA,
   7. et al.

   (2020) The species severe acute respiratory syndrome-related coronavirus:classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 5:536–544.

   OpenUrl
3. ↵
   1. Rabi FA,
   2. Al Zoubi MS,
   3. Kasasbeh GA,
   4. Salameh DM,
   5. Al-Nasser AD

   (2020) SARS-CoV-2 and Coronavirus Disease 2019:What We Know So Far. Pathogens 9:3.

   OpenUrl
4. ↵
   1. Khan S,
   2. Siddique R,
   3. Shereen MA,
   4. Ali A,
   5. Liu J,
   6. Bai Q,
   7. et al.

   (2020) Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2:Biology and Therapeutic Options. J Clin Microbiol 58:5.

   OpenUrl
5. ↵
   1. Syed A

   (2020) Coronavirus:A mini review. Int J Curr Res Med Sci 6:8–10.

   OpenUrl
6. ↵
   1. Guan WJ,
   2. Ni ZY,
   3. Hu Y,
   4. Liang WH,
   5. Ou CQ,
   6. He JX,
   7. et al.

   (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382:1708–1720.

   OpenUrlCrossRefPubMed
7. ↵
   1. Gandhi RT,
   2. Lynch JB,
   3. Del Rio C

   (2020) Mild or Moderate Covid-19. N Engl J Med, 10.1056.
8. ↵
   1. Lauer SA,
   2. Grantz KH,
   3. Bi Q,
   4. Jones FK,
   5. Zheng Q,
   6. Meredith HR,
   7. et al.

   (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases:Estimation and application. Ann Intern Med 172:577–582.

   OpenUrlCrossRefPubMed
9. ↵
   1. Rothan HA,
   2. Byrareddy SN

   (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433.

   OpenUrlCrossRefPubMed
10. ↵
    1. Ye F,
    2. Xu S,
    3. Rong Z,
    4. Xu R,
    5. Liu X,
    6. Deng P,
    7. et al.

    (2020) Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. Int J Infect Dis 94:133–138.

    OpenUrlCrossRefPubMed
11. ↵
    1. Lei S,
    2. Jiang F,
    3. Su W,
    4. Chen C,
    5. Chen J,
    6. Mei W,
    7. et al.

    (2020) Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 21:100331.

    OpenUrl
12. ↵
    1. Munn Z,
    2. Peters MDJ,
    3. Stern C,
    4. Tufanaru C,
    5. McArthur A,
    6. Aromataris E

    (2018) Systematic review or scoping review?Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol 18:143.

    OpenUrlPubMed
13. ↵
    1. Arksey H,
    2. O'Malley L

    (2005) Scoping studies:towards a methodological framework. Int J Soc Res Methodol 8:19–23.

    OpenUrlCrossRef
14. ↵
    1. Tricco AC,
    2. Lillie E,
    3. Zarin W,
    4. O'Brien K,
    5. Colquhoun H,
    6. Kastner M,
    7. et al.

    (2016) A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol 16:15.

    OpenUrlPubMed
15. ↵
    1. World Health Organization

    Eastern Mediterranean region COVID-19 affected countries, cited 2020 April 29, Available from: https://covid19.who.int/.
16. ↵
    1. Borenstein M,
    2. Hedges LV,
    3. Higgins J,
    4. Rothstein HR

    (2014) Comprehensive Meta-Analysis (Version 3) (Biostat, Englewood (NJ)).
17. ↵
    (2019) Stata MPtE 16.0 (StataCorp, College Station, TX) Available from URL: www.stata.com.
18. ↵
    1. World Health Organization

    WHO Coronavirus Disease (COVID-19) Dashboard:Word Health Organization, cited 2020 May 3, Available from: https://covid19.who.int/.
19. ↵
    1. Boswer AD

    Real-world shortages not addressed in new COVID-19 Guidance, Available from: https://www.medscape.com/viewarticle/927209 p. cited 2020;Accessed 2020 May 6.
20. ↵
    1. Davies SE,
    2. Kamradt-Scott A,
    3. Rushton S

    (2015) Disease diplomacy:international norms and global health security. International Affairs 91:1178–1180.

    OpenUrl
21. ↵
    1. Liberati A,
    2. Altman DG,
    3. Tetzlaff J,
    4. Mulrow C,
    5. Gøtzsche PC,
    6. Ioannidis JPA,
    7. et al.

    (2009) The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions:Explanation and Elaboration. PLOS Medicine 6:e1000100.

    OpenUrl
22. ↵
    1. Bedford J,
    2. Enria D,
    3. Giesecke J,
    4. Heymann DL,
    5. Ihekweazu C,
    6. Kobinger G,
    7. et al.

    (2020) COVID-19:towards controlling of a pandemic. Lancet 395:1015–1018.

    OpenUrlCrossRefPubMed
23. ↵
    1. Garg S,
    2. Kim L,
    3. Whitaker M,
    4. O'Halloran A,
    5. Cummings C,
    6. Holstein R,
    7. et al.

    (2020) Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30 2020. MMWR Morb Mortal Wkly Rep 69:458–464.

    OpenUrlCrossRefPubMed
24. ↵
    1. Johns Hopkins University &Medicine

    Mortality Analyses, updated 2020;accessed 2020 May 2, Available from: https://coronavirus.jhu.edu/data/mortality.
25. ↵
    1. Wei WE,
    2. Li Z,
    3. Chiew CJ,
    4. Yong SE,
    5. Toh MP,
    6. Lee VJ

    (2020) Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16 2020. MMWR Morb Mortal Wkly Rep 69:411–415.

    OpenUrlCrossRefPubMed
26. ↵
    1. NYC Health

    Age-adjusted rates of lab confirmed COVID-19 non-hospitalized cases, estimated non-fatal hospitalized cases, and patients known to have died 100,000 by race/ethnicity group as of April 16 2020, Updated 2020;Accessed 2020 May 15, Available from: https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-04162020-1.pdf.
27. ↵
    1. Verity R,
    2. Okell LC,
    3. Dorigatti I,
    4. Winskill P,
    5. Whittaker C,
    6. Imai N,
    7. et al.

    (2020) Estimates of the severity of coronavirus disease 2019:a model-based analysis. Lancet 20:669–677.

    OpenUrl
28. ↵
    1. Ministry of Health

    Ministry of Health continues with active surveillance, COVID-19 monitoring committee stresses, Updated 2020, Available from: https://www.moh.gov.sa/en/Ministry/MediaCenter/News/Pages/News-2020-04-18-003.aspx. Accessed 2020 May 2.
29. ↵
    1. Garske T,
    2. Legrand J,
    3. Donnelly CA,
    4. Ward H,
    5. Cauchemez S,
    6. Fraser C,
    7. et al.

    (2009) Assessing the severity of the novel influenza A/H1N1 pandemic. BMJ 339:b2840.

    OpenUrlFREE Full Text
30. ↵
    1. Epidemiology Working Group for NCIP. Epidemic Response, Chinese Center for Disease Control and Prevention [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]

    (2020) Zhonghua Liu Xing Bing Xue Za Zhi 41:145–151, Chinese.

    OpenUrlCrossRefPubMed
31. ↵
    1. Dietz W,
    2. Santos-Burgoa C

    (2020) Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring) 28:1005.

    OpenUrl
32. ↵
    1. Guan WJ,
    2. Liang WH,
    3. Zhao Y,
    4. Liang HR,
    5. Chen ZS,
    6. Li YM,
    7. et al.

    (2020) Comorbidity and its impact on 1590 patients with Covid-19 in China:A Nationwide Analysis. Eur Respir J 55:2001227.

    OpenUrlAbstract/FREE Full Text
33. ↵
    1. Centers for Disease Control and Prevention

    Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare Settings (Interim Guidance) USA:Centers for Disease Control and Prevention, Updated 2020, Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html. Accessed 2020 May 2.
34. ↵
    1. Young BE,
    2. Ong SWX,
    3. Kalimuddin S,
    4. Low JG,
    5. Tan SY,
    6. Loh J,
    7. et al.

    (2020) Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 323:1488–1494.

    OpenUrlCrossRefPubMed
35. 1. Rothe C,
    2. Schunk M,
    3. Sothmann P,
    4. Bretzel G,
    5. Froeschl G,
    6. Wallrauch C,
    7. et al.

    (2020) Transmission of 2019-nCoV infection from an Asymptomatic Contact in Germany. N Engl J Med 382:970–971.

    OpenUrlCrossRefPubMed
36. ↵
    1. Cai J,
    2. Xu J,
    3. Lin D,
    4. Yang Z,
    5. Xu L,
    6. Qu Z,
    7. et al.

    (2020) A Case Series of children with 2019 novel coronavirus infection:clinical and epidemiological features. Clin Infect Dis, ciaa198, doi:10.1093/cid/ciaa198.
37. ↵
    1. Centers for Disease Control and Prevention

    COVID-19 in Racial and Ethnic Minority Groups:Centers for Disease Control and Prevention, Updated 2020, Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html. Accessed 2020 May 4.
38. ↵
    1. Rodríguez H,
    2. Donner W,
    3. Trainor J

    1. Bolin B,
    2. Kurtz LC

    (2018) in Handbook of Disaster Research Handbooks of Sociology and Social Research, Race, Class, Ethnicity, and Disaster Vulnerability, eds Rodríguez H, Donner W, Trainor J (Springer, Cham) 10.1007/978-3-319-63254-4_10.
39. ↵
    1. US Bureau of Labor Statistics R

    (2019) Labor force characteristics by race and ethnicity 2018:US Bureau of Labor Statistics, Updated 2019, Available from: https://www.bls.gov/opub/reports/race-and-ethnicity/2018/home.htm. Accessed 2020 May 5.